Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$14.65
-0.3%
$13.91
$10.57
$33.33
$2.13B1.321.12 million shs1.10 million shs
Immunocore Holdings plc stock logo
IMCR
Immunocore
$36.07
-3.2%
$30.36
$23.15
$42.09
$1.81B0.83370,807 shs777,933 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$136.08
-0.6%
$148.95
$122.80
$219.34
$3.93B0.65312,163 shs342,345 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$40.58
-1.2%
$38.09
$29.17
$62.40
$7.56B1.11.52 million shs1.01 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-0.34%+4.94%+1.81%-2.59%-29.47%
Immunocore Holdings plc stock logo
IMCR
Immunocore
-3.17%-6.68%+27.01%+26.92%-13.46%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-0.63%+8.55%+2.91%-26.40%-17.24%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-1.24%-0.17%0.00%+4.35%+0.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
4.3167 of 5 stars
4.51.00.04.72.22.50.0
Immunocore Holdings plc stock logo
IMCR
Immunocore
2.7945 of 5 stars
4.30.00.00.02.54.20.0
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.5608 of 5 stars
3.51.00.04.72.53.31.9
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.8726 of 5 stars
4.50.00.04.70.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3.06
Buy$33.71130.13% Upside
Immunocore Holdings plc stock logo
IMCR
Immunocore
2.55
Moderate Buy$58.8963.26% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$211.1355.15% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$67.0865.31% Upside

Current Analyst Ratings Breakdown

Latest RVMD, DNLI, KRYS, and IMCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00
5/27/2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00
5/19/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $27.00
5/16/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.00
5/14/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$73.00 ➝ $72.00
5/8/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $29.00
5/8/2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$67.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$87.00 ➝ $80.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M6.44N/AN/A$7.42 per share1.97
Immunocore Holdings plc stock logo
IMCR
Immunocore
$333.58M5.43N/AN/A$7.42 per share4.86
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$333.45M11.79$3.46 per share39.38$32.85 per share4.14
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$742K10,187.00N/AN/A$11.09 per share3.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$145.22M-$2.67N/AN/AN/AN/A-32.94%-30.04%7/30/2025 (Estimated)
Immunocore Holdings plc stock logo
IMCR
Immunocore
-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%8/6/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$10.93M$4.1645.5113.50N/A30.69%11.41%10.40%8/4/2025 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)

Latest RVMD, DNLI, KRYS, and IMCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million
5/7/2025Q1 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.12-$1.13-$0.01-$1.13N/AN/A
5/6/2025Q1 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A
5/6/2025Q1 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.38$1.20-$0.18$1.20$98.66 million$88.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
Immunocore Holdings plc stock logo
IMCR
Immunocore
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/A
9.98
9.98
Immunocore Holdings plc stock logo
IMCR
Immunocore
1.03
3.78
3.76
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
7.28
7.76
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
14.24
14.24

Institutional Ownership

CompanyInstitutional Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
Immunocore Holdings plc stock logo
IMCR
Immunocore
84.50%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12.50%
Immunocore Holdings plc stock logo
IMCR
Immunocore
10.40%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.70%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430145.28 million132.55 millionOptionable
Immunocore Holdings plc stock logo
IMCR
Immunocore
32050.23 million45.48 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.90 million24.71 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.27 million154.76 millionOptionable

Recent News About These Companies

Revolution Medicines Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$14.65 -0.05 (-0.34%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$14.67 +0.02 (+0.14%)
As of 07:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Immunocore stock logo

Immunocore NASDAQ:IMCR

$36.07 -1.18 (-3.17%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$36.01 -0.06 (-0.16%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$136.08 -0.86 (-0.63%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$135.72 -0.37 (-0.27%)
As of 06/9/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$40.58 -0.51 (-1.24%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$40.59 +0.01 (+0.02%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.